Miniaturized Vital Sign Monitoring for Newborns in the Delivery Room
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Alyssa Maximov, BSc.
- Phone Number: 78229 5149341934
- Email: alyssa.maximov@muhc.mcgill.ca
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Infants born by C-Section or vaginal delivery, with ≥35 weeks of gestational age and judged clinically stable immediately after birth.
Exclusion Criteria:
- Infants with skin abnormality would potentially increase the risk of injury.
- Family experiencing too much stress as determined by an attending physician or bedside care team, to not be approached for recruitment.
- Infants born at <35 weeks gestational age.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Newborn Infants
Healthy newborn infants enrolled in the study who will undergo simultaneous monitoring with the Wireless MicroPremVitals Button Sensor System and standard-of-care monitoring in the delivery room to evaluate the accuracy, safety, and feasibility of the wireless monitoring system.
|
A wireless wearable sensor system applied to newborn infants in the delivery room to continuously measure electrocardiography (ECG), heart rate, respiratory rate, oxygen saturation, and skin temperature.
Measurements will be compared with standard-of-care monitoring for validation purposes only and will not be used for clinical decision-making.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Electrocardiography (ECG) Accuracy
Time Frame: During two 15-minute monitoring periods within the first 90 minutes after birth
|
Agreement between ECG measurements obtained using the Wireless MicroPremVitals Button Sensor System and the standard-of-care Dräger Infinity M540 monitor.
|
During two 15-minute monitoring periods within the first 90 minutes after birth
|
|
Skin Temperature Accuracy
Time Frame: During two 15-minute monitoring periods within the first 90 minutes after birth.
|
Agreement between skin temperature measurements obtained using the Wireless MicroPremVitals Button Sensor System and the standard-of-care Dräger Infinity M540 monitor.
|
During two 15-minute monitoring periods within the first 90 minutes after birth.
|
|
Oxygen Saturation (SpO₂) Accuracy
Time Frame: During two 15-minute monitoring periods within the first 90 minutes after birth.
|
Agreement between oxygen saturation (SpO₂) measurements obtained using the Wireless MicroPremVitals Button Sensor System and the standard-of-care Dräger Infinity M540 monitor.
|
During two 15-minute monitoring periods within the first 90 minutes after birth.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart Rate Accuracy
Time Frame: During two 15-minute monitoring periods within the first 90 minutes after birth.
|
Heart rate will be calculated offline from raw optical and motion data collected by the Wireless MicroPremVitals Button Sensor System.
Agreement between calculated heart rate and the standard-of-care Dräger Infinity M540 monitor will be evaluated.
|
During two 15-minute monitoring periods within the first 90 minutes after birth.
|
|
Heart Rate Variability (HRV)
Time Frame: During two 15-minute monitoring periods within the first 90 minutes after birth.
|
Heart rate variability will be calculated offline from raw optical and motion data collected by the Wireless MicroPremVitals Button Sensor System.
Derived HRV measurements will be compared with HRV derived from the standard-of-care Dräger Infinity M540 monitor.
|
During two 15-minute monitoring periods within the first 90 minutes after birth.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Guilherme Sant'Anna, MD, PhD, RI-MUHC
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- Button Sensors in the DR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.